Rationale: 7-Ketocholesterol (7-KC), a form of cholesterol oxidation product, plays an essential role in the atherogenesis in animal models.
A therosclerosis is the leading cause of death and disability worldwide, and its prevalence is expected to increase in the coming years. The pathogenesis of atherosclerosis is characterized by the development of fibrofatty plaques, 1, 2 which is involved in part mediated by inflammatory and oxidative mechanisms. [2] [3] [4] Oxidative modification of low-density lipoprotein (LDL) to oxidized LDL is widely regarded as a crucial early event in the initiation and progression of atherosclerosis. LDL may be subjected to retention and aggregation in the subendothelial spaces of the arterial wall where it is oxidatively modified by various mechanisms. 3, 4 Concomitant with the oxidative changes of LDL, there is a marked increase in cholesterol oxidation products especially oxysterols, which are generated nonenzymatically after oxygen free radicals attack on cholesterol. [5] [6] [7] In addition, oxysterols may be originally present in the diet 8, 9 and readily incorporated into plasma lipoproteins. 10 Dietary sources of oxysterols are cholesterol-rich foods (such as dairy, egg, and meat products), especially those products that are heated in air during processing or are stored for long periods of time. 8, 9 Among the oxysterols that have been identified, those oxidized at the C7 position have been shown to contribute to endothelial cell dysfunction, which characterizes the onset of the atheromas. 11 Compared with other oxysterols, 7-ketocholesterol (7-KC) is more abundantly presented in the blood of patients with hypercholesterolemia and in human atherosclerotic lesions. [12] [13] [14] Cellular accumulation of 7-KC promotes oxidative stress, endoplasmic reticulum stress, and apoptosis in macrophages, causing macrophage necrosis and advanced lesion development. 12, 15, 16 Induction of 7-KC efflux from macrophages protects against endothelial dysfunction and prevents atherogenesis in mice fed a high-cholesterol diet. 17 Although 7-KC might be a promising therapeutic target for atherosclerotic cardiovascular disease, the clinical relevance of the association between 7-KC and incident cardiovascular adverse outcomes remains still uncertain. Therefore, in this study, we prospectively evaluated the prognostic value of plasma 7-KC levels in patients with stable coronary artery disease (CAD).
Methods

Study Participants
Study participants were recruited between October 2008 and December 2011 as part of the Expanded Guangdong Coronary Artery Disease Cohort (EGCADC). EGCADC consisted of patients aged from 40 to 80 years old recruited from GCADC and outpatients from Guangdong General Hospital following the same inclusion and exclusion criteria, ascertainment of CAD, questionnaires and study protocol. A total of 2523 CAD patients were included in the EGCADC (1513 from GCADC and another 1010 from Guangdong General Hospital). The recruitment methods and study design have been previously demonstrated. 18, 19 Patients were eligible if they met at least one of the following criteria: history of myocardial infarction (MI) or coronary revascularization, angiographic evidence of at least 50% stenosis in at least 1 coronary vessel, or documented diagnosis of CAD by an internist or cardiologist. The exclusion criteria were as follows: inability to walk 1 block; MI within the past 6 months; any malignancy; missing or incomplete angiographic data; and missing blood samples, laboratory measurements, or cause of death information. The patients were enrolled from the Cardiology Department across 4 major general hospitals between 2008 and 2011 in Guangzhou city. A total of 1016 participants with stable CAD from EGCADC were enrolled into the final analysis.
All study participants were interviewed to collect information on demographic characteristics, medical history, medication use, behavioral habits, and risk factor prevalence at the baseline. Current smoking was classified as smoking at least 1 cigarette per day and lasting more than half a year. Alcohol drinking was defined as drinking any type of alcoholic beverage at least once a week and lasting beyond 6 months. Medical records were reviewed to confirm a history of MI and other conditions and to document previous angiographic findings and previous coronary revascularization. This study complies with the Declaration of Helsinki. The Institutional Review Board at Sun Yat-sen University approved the study protocol. All participants provided written informed consent at the time of enrollment.
Baseline Measurements
An overnight fasting blood sample was collected to measure plasma lipids and glucose levels. Body mass index was calculated as an individual's weight in kilograms divided by the square of height in meters. The systolic blood pressure and diastolic blood pressure were measured 3× with 5-minute intervals in the morning. Hypertension was defined as a mean blood pressure of ≥140/90 mm Hg or self-reported use of antihypertensive medication, and diabetes mellitus was diagnosed as a fasting plasma glucose level ≥7.0 mmol/L, postprandial plasma glucose level ≥11.1 mmol/L, or self-reported use of antidiabetic medication. Plasma lipid levels were measured enzymatically by using an automatic analyzer (Hitachi 747 autoanalyzer; Hitachi Ltd, Tokyo, Japan). Serum levels of interleukin 6 (IL-6) and VCAM-1 (vascular cell adhesion molecule 1) were determined by using commercial Quantikine ELISA Human Immunoassay Kit provided by R&D Systems Inc (Minneapolis, MN) according to the manufacturer's instructions. The mean interassay and intra-assay coefficients of variation were 6.4% and 7.8% for IL-6, and 4.2% and 3.5% for VCAM-1. Plasma concentrations of high-sensitivity C-reactive protein (hsCRP) were determined using a high-sensitivity turbidimetric 
Novelty and Significance
What Is Known?
• 7-Ketocholesterol (7-KC), a form of cholesterol oxidation product, promotes oxidative stress, endoplasmic reticulum stress, and apoptosis in macrophages, contributing to the atherogenesis in animal models. • 7-KC is more abundantly presented in the circulation of patients with hypercholesterolemia and in human atherosclerotic lesions.
What New Information Does This Article Contribute?
• High plasma 7-KC levels are associated with increased risk of adverse end points such as all-cause death, myocardial infarction, and heart failure hospitalization among patients with stable coronary artery disease (CAD).
• Prognostic value provided by plasma 7-KC is additional and independent of established risk factors and available measures of CAD severity.
The 7-KC is one of the major oxygenated products found in oxidized LDL and closely relevant to the lipid-related disorders. Previous studies had reported the potential proatherogenic effects of 7-KC in animal studies. However, the clinical implication of circulating 7-KC in the prediction of cardiovascular events and death in CAD patients is not still unknown. This study showed that the plasma 7-KC level is independently associated with higher rates of incident cardiovascular events and overall death in patients with stable CAD. Even after adjustment for established risk factors and available measures of CAD severity, the plasma 7-KC level is associated with adverse outcomes in a contemporary cohort of patients with stable CAD. This finding needs to be substantiated by more population studies.
assay (Roche Diagnostics, Basel, Switzerland). The intra-assay and interassay coefficient of variation for all of the measured biochemical parameters was <5%. The plasma homocysteine concentrations were measured by high-performance liquid chromatography with fluorescence detection. 19 The plasma NT-proBNP (N-terminal pro-Btype natriuretic peptide) was measured using Elecsys proBNP immunoassay kit (Roche Diagnostics). The glomerular filtration rate (GFR) was estimated as per the most recent Modification of Diet in Renal Disease Study equation for standardized serum creatinine. Left ventricular ejection fraction (LVEF) was calculated as end-diastolic volume minus end-systolic volume divided by end-diastolic volume.
Metabolic syndrome (MetS) was defined using the updated National Cholesterol Education Program/Adult Treatment Panel III criteria for Asian Americans as having ≥3 of the following components: waist circumference ≥90 cm for men or ≥80 cm for women, triglycerides ≥1.7 mmol/L, high-density lipoprotein (HDL) cholesterol <1.03 mmol/L for men or <1.30 mmol/L for women, blood pressure ≥130/ 85 mm Hg or current use of antihypertensive drugs, or fasting blood glucose ≥5.6 mmol/L.
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Plasma 7-KC Assay
The plasma 7-KC level was measured as previously described. 21, 22 Plasma samples were routinely collected in tubes containing ethylene diamine tetraacetic acid K3 and butylated hydroxytoluene and immediately centrifuged. The plasma was isolated and stored at −80°C before analysis. The internal standard solution of 100 μL (CND Isotopes, Quebec, Canada) was added to 25 μL plasma. The mixture was vigorously mixed and centrifuged at a speed of 13 500 rcf for 5 min at room temperature, following which the supernatant was transferred to a 96-well plate. Analysis was performed on a ultraperformance liquid chromatography system with a Xevo TQ MS detector (Waters, Milford, MA). 7-KC was detected using positive electrospray ionization through multiple reaction monitoring modes. The recovery of plasma 7-KC was in the approximately range of 85% to 95%. All plasma samples were run in duplicate, and the values were averaged. The mean intra-and interassay coefficient of variation was 4.1% and 7.8%, respectively. The detection limit of this assay was 14.1 nmol/L, and no value was below the limit in our measurements. The plasma 7-KC level was measured within 1 month because the participant was recruited in the cohort. All stored samples were used under argon, which may have prevented occasional cholesterol oxidation products formation.
Prospective Follow-Up and Outcomes Determination
The cohort was prospectively followed up for determination of the primary outcome of all-cause death, the secondary outcomes of cardiovascular events, including MI, hospitalization because of heart failure (HF), cardiovascular death, and the composite end point of MI/hospitalization HF/death. We conducted annual follow-up interviews with the participants (or their relatives) to inquire about interval hospitalizations or death. For each reported event, medical records, electrocardiograms, death certificates, autopsy reports, and coroner's reports were acquired. Each event was adjudicated by 2 independent and blinded physician adjudicators. If the disagreement occurred, the adjudicators conferred, reconsidered their classification, and requested consultation from a third blinded adjudicator. The median follow-up time was 4.6 years (interquartile range, 3.6-5.5 years). MI was defined according to the using standard diagnostic criteria. 23 Hospitalization of HF was defined as a hospital readmission for which HF was the primary reason based on the Framingham congestive HF criteria. Death and cause of death were verified by death certificates and review of medical records and coroner's reports. 24 Cardiovascular death was defined as death attributable to an ischemic cardiovascular cause (fatal MI, ischemic stroke, and peripheral arterial disease) or sudden death not explained by other causes but presumed cardiovascular cause in high-risk patients.
Statistical Analysis
Participants were categorized into quartiles based on the quartile of plasma 7-KC level. Continuous variables are presented as means±SD or median with interquartile range and categorical variables as counts and percentages (%) with 1-way ANOVA and the χ 2 test used to determine differences between groups. We calculated event rates per 100 person-years by quartile of 7-KC level for MI, hospitalization of HF, cardiovascular death, all-cause death, and the composite end points of MI/HF/death. Event rates by quartile were compared using the Mantel-Haenszel test for trend and Cox proportional hazards regression models. We constructed Kaplan-Meier curves according to the quartile of plasma 7-KC level and compared the composite end point of MI/ HF/death across groups using the log-rank test. The hazard ratio (HR) and 95% confidence interval (CI) of the outcomes of the composite of all events according to increasing quartile of 7-KC was calculated with Cox proportional hazards models adjusted for traditional cardiovascular risk factors. Two models were constructed with adjustments for the following covariates: model 1 was adjusted for age and sex; model 2 was adjusted for model 1 covariates plus body mass index; current smoking; history of MI; hypertension; diabetes mellitus; medication usage, including statin, aspirin, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and β-blocker; estimated glomerular filtration rate (eGFR); HDL cholesterol; LDL cholesterol; IL-6; hsCRP; NT-proBNP; and Gensini score. The circulating levels of hsCRP, NTproBNP, and 7-KC were normalized by log 10 transformation.
To evaluate the interplay between 7-KC and LDL cholesterol in risk estimation of composite of cardiovascular outcome and total death, we divided the participants in 4 groups: low 7-KC and low LDL cholesterol, high 7-KC and low LDL cholesterol, low 7-KC and high LDL cholesterol, and high 7-KC and high LDL cholesterol. We used median as the cutoff value, and below median was defined as low level, whereas above median was recognized as high level. Using the group with low 7-KC-low LDL cholesterol as the reference, we calculated crude and adjusted HR with 95% CI for high 7-KC-low LDL cholesterol, low 7-KC-high LDL cholesterol, and high 7-KC-high LDL cholesterol. Low LDL cholesterol is defined as ≤3.37 nmol/L (below median) and high LDL cholesterol >3.37 nmol/L (above median).
To further evaluate the interplay between plasma 7-KC and serum CRP in risk estimation of primary outcomes, we stratified the study patients in 4 groups: low 7-KC-low CRP, high 7-KC-low CRP, low 7-KC-high CRP, and high 7-KC-high CRP. Low plasma 7-KC is defined as ≤80.2 nmol/L (below median) and high 7-KC >80.2 nmol/L (above median). Low CRP is defined as ≤3 μmg/mL and high CRP as >3 μg/mL according to the risk classification guidelines for cardiovascular disease by American Heart Association. 25 The incremental value of the 7-KC for risk prediction was tested before and after their addition to a clinical model with the following traditional risk predictors: age, sex, body mass index, current smoking, history of MI, hypertension, diabetes mellitus, total and HDL cholesterol levels, and eGFR. And further adjustment for traditional risk factors plus natural logarithm transformed hsCRP and NT-proBNP levels. The C statistics from Cox regression models and integrated discrimination improvement were calculated as a measure of risk discrimination of plasma 7-KC in the prediction of cardiovascular outcomes and death. We set the truncation time at 5 years. The resulting risk discrimination metrics indicate the performance of the given model in predicting events that occurred in the time range from baseline to 5 years. Sensitivity analyses were performed for medication usage that may have potential to alter 7-KC levels, including statin, aspirin, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and β-blocker. Statistical analyses were performed using SPSS 19.0 statistical packages (SPSS Inc, Chicago, IL) and R (3.1.0). A 2-sided P value <0.05 was considered statistically significant.
Results
Baseline Characteristics of Study Patients
The plasma 7-KC concentrations were skewed to the right (Online Figure I) , with a median level of 80.2 nmol/L. The median value of men (81.8 nmol/L) was slightly higher but insignificantly differs with that in women (78.3 nmol/L). Baseline characteristics of the 1016 patients with stable CAD are presented according to quartiles of the plasma 7-KC level (Table 1) . Participants in the third and fourth quartiles of 7-KC were more likely to be older, higher prevalence of hypertension, higher rate of MI history, higher hsCRP, NT-proBNP, and IL-6 levels, worse renal function (lower eGFR), impaired LVEF, and greater CAD burden (higher Gensini score) than those in the first and second quartiles. Partial correlation coefficients adjusted for age and sex are shown in Online Table  I . Plasma 7-KC levels were directly correlated with hsCRP, NT-proBNP, IL-6, and Gensini score but inversely correlated with HDL cholesterol and eGFR.
Association of Plasma 7-KC With Demographic and Clinical Characteristics
The relationship of plasma 7-KC with clinical characteristics and angiographic scores was shown in Online Table II. Higher plasma 7-KC levels were associated with higher age, body mass index, presence of hypertension, higher rate of MI history, high hsCRP, impaired renal function (lower GFR), statin use, impaired left ventricular function (lower LVEF), and greater CAD burden (Gensini score) in the univariate analyses. Among these parameters, age, presence of hypertension, eGFR, LVEF, HDL cholesterol, hsCRP, and Gensini score were independently and significantly associated with plasma 7-KC in a multivariate model.
Association of Plasma 7-KC With the Adverse Outcomes
After a median follow-up of 4.6 years, 148 participants (14.6%) died, 78 participants (7.7%) experienced an MI, 92 participants (9.1%) were hospitalized for HF, and 221 participants (21.8%) experienced a composite end point of cardiovascular event or death (Online Table III ). Participants with high 7-KC levels (quartiles 3 and 4) were more likely to experience composite end points than those with low 7-KC levels (quartiles 1 and 2; Figure 1 ). For individual components of the adverse outcome (MI, hospitalization for HF, cardiovascular death, and all-cause death), we found that higher 7-KC levels were associated with higher rates of each cardiovascular event and total death (Online Table III ). Participants in the highest quartile of 7-KC level (event rate 8.9%) experienced composite of MI/HF/death ≈2.5× than the rate of participants with the lowest 7-KC quartile (event rate 3.5%).
When participants in the highest quartile of 7-KC levels were compared with those in the lowest quartile in unadjusted analysis, the HR for individual cardiovascular outcomes or death ranged from 2.09 to 2.75 and were all statistically significant (P<0.001). These associations were persistent even after adjustment for demographic variables, clinical risk factors, and medication use ( Table 2) .
Kaplan-Meier curves, showing the risk of composite end points, including cardiovascular events and death during the follow-up, demonstrated that participants with high 7-KC levels were more likely to experience adverse outcomes than those with low 7-KC levels ( Figure 2 ).
Subgroup Analyses
We analyzed the relationship of 7-KC with composite end points stratified by participants with or without MetS. Of 221 composite cardiovascular outcome and death, 118 occurred in participants with MetS (n=415), and 103 occurred among subjects without MetS (n=601). In multivariable analyses, 7-KC was significant associated with risk of composite cardiovascular events and death in both metabolic (adjusted HR, 1.67; 95% CI, 1.42-1.96; P<0.001) and nonmetabolic participants (adjusted HR, 2.11; 95% CI, 1.81-2.49; P<0.001; Table 3 ).
We further analyzed the main cardiovascular outcome and death associated with 7-KC by LDL cholesterol level. Using as reference category patients with low 7-KC and low LDL cholesterol, defined as values below the median value of each variable, high 7-KC in absence of elevated LDL cholesterol was observed to associate significantly with risk of composite adverse outcome and death (adjusted HR, 1.33; 95% CI, 1.17-1.53; P=0.009). However, this association was not observed in patients with high LDL cholesterol in absence of elevated 7-KC (adjusted HR, 1.06; 95% CI, 0.91-1.23; P=0.065). Furthermore, patients with high 7-KC and high LDL cholesterol have higher risk of composite end points compared with those with high 7-KC but low LDL cholesterol (adjusted HR, 1.48; 95% CI, 1.28-1.71; P<0.001; Table 4 ).
Both 7-KC and hsCRP were independently associated with risk of adverse outcome of CAD patients, we used high/ low categories to identify the potential value of combining 7-KC and hsCRP measures for predicting future events. In comparison with patients with low 7-KC-low CRP, those with high 7-KC-low CRP had a multivariate adjusted HR of 1.42 (95% CI, 1.25-1.59; P<0.001) for risk of composite cardiovascular events and total death. Patients with high 7-KC-high CRP had a fully adjusted HR of 1.85 (95% CI, 1.64-2.17; P<0.001) compared with those with low 7-KC-low CRP for risk of outcomes (Table 5) .
Sensitivity Analyses
We also performed sensitivity analyses in this study. In sensitivity analysis, we tested the effect of statin use on the association between 7-KC and composite cardiovascular events and death. Overall, 23.1% of the whole cohort reported to have using statins at baseline. The composite cardiovascular events and death were present in 178 (22.8%) of the CAD patients in which statins were not used and 48 (18.3%) in which they were used. There was no 7-KC-statin use interaction (P=0.17).
When a model adjusted for demographic and clinical variables plus statin use at baseline, there was no significant effect on the HR across the quartile of plasma 7-KC. Adding aspirin, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and β-blocker to a model adjusted for demographic and clinical variables plus statin use also did not appreciably change the HR (Online Table IV) .
Compared with the group of nonstatin use, the unadjusted relative risk for composite end points was 32% higher (unadjusted HR, 1.32; 95% CI, 1.07-1.64; P=0.031) than that in the group of statin use. After stratification on age and sex, this increase in risk associated with statin use was substantially attenuated (adjusted HR, 1.26; 95% CI, 1.00-1.58; P=0.05).
With further adjustment for all potential confounders, the apparent increase in risk associated with statin use was no longer present (adjusted HR, 1.17; 95% CI, 0.92-1.45; P=0.076; Online Table V) .
Risk Discrimination Testing Analysis
We finally evaluated the discrimination and reclassification with addition of the 7-KC level. Compared with the baseline model that includes traditional risk factors (C statistic, 0.67; 95% CI, 0.61-0.74), the addition of 7-KC levels increased the C statistic to 0.75 (95% CI, 0.65-0.82; P<0.001), resulting in an integrated discrimination improvement of 5.3% (2.6%-8.3%) and a category-free net reclassification improvement of Model 1, adjusted for age and sex. Model 2, adjusted for model 1 plus body mass index, current smoking, history of MI, hypertension, diabetes mellitus, medication usage, including statin, aspirin, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and β-blocker, glomerular filtration rate, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, interleukin 6, high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and Gensini score. 7-KC indicates 7-ketocholesterol; CV, cardiovascular; CI, confidence interval; HF, heart failure; HR, hazard ratio; and MI, myocardial infarction.
40% (23%-56%).
Compared with the baseline model of clinical risk factors plus NT-proBNP and hsCRP, the addition of 7-KC increased the C statistic from 0.79 (95% CI, 0.72-0.86) to 0.82 (0.74-0.88; P=0.032), resulting in an integrated discrimination improvement of 1.5% (0.6%-3.2%) and a category-free net reclassification improvement of 14% (1.5%-30%; Table 6 ). There was no evidence of poor calibration in any model (all goodness-of-fit tests, P>0.10).
Discussion
In this cohort study, including 1016 participants with stable CAD, we found an increased risk of incident all-cause death, MI, and HF hospitalization among participants with higher baseline circulating 7-KC levels. These relationships remained significant even after adjustment for demographic and clinical covariates. Furthermore, the plasma 7-KC level added incremental predictive value to the clinical risk factors by using risk discrimination indices. To the best of our knowledge, this is the first study to investigate the association of 7-KC, a cholesterol oxidation product that putatively regulates the degenerative disorders in mice, 22 with cardiovascular outcomes and all-cause mortality in a CAD cohort. Future studies are needed to confirm that whether 7-KC could serve as a biochemical marker of adverse events of CAD.
The 7-KC is one of the major oxygenated products found in oxidized LDL and closely relevant to the lipid-related disorders. Previous population studies had reported the potential proatherogenic effects of 7-KC. Elevated circulating 7-KC was found to be associated with higher levels of cholesterol, including total, non-HDL and LDL cholesterol, and apolipoprotein B levels in adolescents. 26 Furthermore, a case-control study observed that serum 7-KC was significantly higher in Model 1, adjusted for age and sex. Model 2, adjusted for model 1 plus body mass index, current smoking, history of myocardial infarction, hypertension, diabetes mellitus, medication usage, including statin, aspirin, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and β-blocker, glomerular filtration rate, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, interleukin 6, high-sensitivity C-reactive protein (hsCRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and Gensini score. 7-KC indicates 7-ketocholesterol; CI, confidence interval; HR, hazard ratio; and MetS, metabolic syndrome. Model 1, adjusted for age and sex. Model 2, adjusted for model 1 plus body mass index, current smoking, history of myocardial infarction, hypertension, diabetes mellitus, medication usage, including statin, aspirin, angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), and β-blocker, glomerular filtration rate, high-density lipoprotein cholesterol, interleukin 6, high-sensitivity C-reactive protein (hsCRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and Gensini score. Low plasma 7-KC is defined as ≤80.2 nmol/L (below median) and high 7-KC >80.2 nmol/L (above median). Low LDL cholesterol is defined as ≤3.37 nmol/L (below median) and high LDL cholesterol >3.37 nmol/L (above median). 7-KC indicates 7-ketocholesterol; CI, confidence interval; HR, hazard ratio; and LDL, low-density lipoprotein.
subjects with CAD than in those with normal coronary artery, and multiple regression analysis revealed that 7-KC was an independent variable for CAD progression. 27 Unfortunately, the cross-sectional study design and the relatively small sample size did not allow for determination of clinical value of circulating 7-KC levels in the prediction of cardiovascular events and death. Our study confirms and further extends these findings in 3 important aspects. First, we found that 7-KC is stable and can be reproducibly detected in >90% of patients with CAD. Second, we showed that the 7-KC level is associated with the risk of adverse outcomes of cardiac functional abnormalities and cardiovascular complements, such as MI, HF, and cardiovascular death. Third, we demonstrated that, even after adjustment for established risk factors and available measures of CAD severity, the plasma 7-KC level is associated with adverse outcomes in a contemporary cohort of patients with stable CAD. Taken together with the studies in mice, our findings support the hypothesis that 7-KC is a circulating metabolite of cholesterol that deteriorates adverse cardiovascular events and death.
MetS may be diagnosed when a patient has a cluster of risk factors for CAD. In our study, we did not observe the interaction of 7-KC with MetS categories. Higher 7-KC was associated with incident composite outcome not only in MetS patients but also in non-MetS subjects, suggesting that presence of MetS may not be a residual confounding factor in this study. Thus, the relationship between 7-KC and adverse outcomes was likely not to be dependent on the presence of MetS. Our observation also showed that association between elevated 7-KC and the risk of composite adverse outcomes risk was independent of high LDL cholesterol. LDL cholesterol elevation failed to predicts the risk of composite end points alone. Moreover, patients with high 7-KC-high LDL cholesterol had almost similar HR of adverse events and death in contrast to patients with high 7-KC-low LDL cholesterol in multivariate adjusted model. These findings further supported the critical role of 7-KC that goes far beyond a major component of oxidized LDL. 28 The underlying mechanisms by which increased circulating 7-KC is associated with cardiovascular events and death are unknown. Although 7-KC was a potent inducer of oxidative damage, the associations of plasma 7-KC with cardiovascular events and total death in stable CAD patients could primarily not be explained by the oxidative stress. Plasma 7-KC was demonstrated to be positively correlated with proinflammatory markers, including hsCRP and IL-6, according to the multivariate analyses. Whether CRP represents a cardiovascular risk factor with bioactive properties related to atherogenesis or rather a risk biomarker of general chronic inflammation is not consistent. 25 Despite this, the finding that a combined increase of 7-KC and hsCRP seemed to be more strongly associated with mortality than an increase in each biomarker alone strengthens the theory that 7-KC and CRP may reflect different features of inflammation. Furthermore, a large number of studies report a positive association between circulating IL-6 concentration and the risk of mortality from CAD. [29] [30] [31] Thus, Model 1, adjusted for age and sex. Model 2, adjusted for model 1 plus body mass index, current smoking, history of myocardial infarction, hypertension, diabetes mellitus, medication usage, including statin, aspirin, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and β-blocker, glomerular filtration rate, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, interleukin 6, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and Gensini score. Low plasma 7-KC is defined as ≤82.2 nmol/L and high 7-KC >82.2 nmol/L. Low CRP is defined as ≤3 μmg/mL and high CRP as >3 μg/mL. 7-KC indicates 7-ketocholesterol; CI, confidence interval; HR, hazard ratio; and hsCRP, high-sensitivity C-reactive protein. Both hsCRP and NT-proBNP levels are natural logarithm transformed. 7-KC indicates 7-Ketocholesterol; CI, confidence interval; hsCRP, high-sensitivity C-reactive protein; and NT-proBNP, N-terminal pro-B-type natriuretic peptide.
*Adjusted for age, sex, body mass index, current smoking, history of myocardial infarction, hypertension, diabetes mellitus, high-density lipoprotein cholesterol, low-density lipoprotein, and estimated glomerular filtration rate.
†P=0 oxidative stress and systemic inflammation may coexist and contribute to the development of adverse outcomes of CAD. Further studies are needed to evaluate the value of 7-KC in addition to CRP and other cytokines and inflammatory mediators in cardiovascular risk prediction. More importantly, 7-KC had been previously proved to be an enticement of smooth muscle cells apoptosis, 32 extracellular matrix breakdown, 33 fibrous cap formation, 34, 35 platelet adhesion, 36 and aggregation, 37 critical steps in the initiation and development of atherothrombosis. All these features were demonstrated fully as potent enhancer of plaque instability, acute vascular events, and death. The plasma levels of 7-KC are stable and can be reproducibly measured in our study and exhibit only modest withinsubject variation, which augurs well for its use as clinical biomarkers for prediction of clinical adverse end point under the CAD status. Thus, circulating 7-KC may additionally serve as metrics for monitoring the clinical course of CAD. Although relationship of the 7-KC with disease progression is limited by the pleiotropic nature of the disease, we were able to demonstrate significant correlations between plasma concentrations of 7-KC and CAD severity and outcome.
The strengths of this study include its population-based prospective design, which comprised a large sample size of patients with angiography-confirmed CAD, a relatively long duration of follow-up, and a high participation rate which may increase the generalizability and reduce the risks of selection bias. In addition, it is the largest study to use 7-KC as an oxysterol biomarker in a prospective cohort with comparable numbers of women and men. Finally, this study used multiple clinical outcomes and detailed biochemical measurements and explored the interaction of 7-KC with hsCRP.
Several limitations of this study also merit comment. First, our study population only comprised CAD patients of Chinese origin who are not representative of the general populations, and, therefore, our findings may not be generalizable or applicable to other ethnicities. Then, plasma 7-KC was only measured once in baseline, and concentrations may fluctuate during the follow-up because of dietary patterns changes and lifestyle variation. Data on the dietary information were not available; we, therefore, cannot exclude that high 7-KC concentrations are caused by changed dietary patterns. Finally, the observational nature of this study does not allow us to infer causality, and CAD may have been a confounding factor in our results.
In summary, our study showed that the plasma 7-KC level is independently associated with higher rates of incident cardiovascular events and overall death in patients with stable CAD. This finding needs to be substantiated by more population studies.
